Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Zepbound works by slowing gastric emptying to suppress appetite and improve blood sugar control, but this same mechanism often leads to drier, harder stools; most people manage it with dietary fiber, hydration, exercise, probiotics, or over-the-counter aids, while persistent or severe symptoms may call for dose adjustments or a switch in therapy.
There are several important factors to consider—from warning signs like severe cramps or blood in stool to alternative medications and timing tweaks—so see below for a full guide before making any decisions about your treatment.
Zepbound (a glucagon-like peptide-1 or GLP-1 receptor agonist) is increasingly prescribed for weight management and type 2 diabetes. While many patients see impressive results in appetite control and blood sugar regulation, a common side effect is constipation. This guide explains why does Zepbound cause constipation, how to manage it, and when to consider switching medications. If you ever experience severe or persistent issues, be sure to speak to a doctor—especially if you notice alarming symptoms like severe abdominal pain, blood in stool, or unexplained weight loss.
Zepbound mimics the naturally occurring hormone GLP-1. By stimulating GLP-1 receptors, it:
Slowing gastric motility is key to Zepbound's efficacy—but it's also the main reason for constipation.
Why does Zepbound cause constipation? The answer lies in its core mechanism:
Delayed Gastric Emptying
• Zepbound slows the movement of food from the stomach to the small intestine.
• This delay often continues down the digestive tract, reducing motility in the colon.
Altered Fluid Absorption
• When stool moves more slowly, the colon has extra time to absorb water.
• Drier, harder stools are more difficult to pass.
Changes in Appetite and Diet
• Reduced hunger can lead to lower overall food and fluid intake.
• Less fiber and water in the diet exacerbate constipation.
Individual Variability
• Some people naturally have slower gut motility or are predisposed to constipation.
• Combination with other medications (e.g., certain painkillers) can worsen the effect.
Most people can improve symptoms without stopping Zepbound. Try these strategies:
If you're experiencing persistent digestive discomfort and want to better understand your symptoms, try Ubie's free AI-powered Constipation symptom checker to help determine whether your symptoms require medical attention.
Constipation alone usually doesn't require switching off Zepbound. However, consult your healthcare provider if you experience:
Your doctor may recommend:
Before making any changes, weigh Zepbound's benefits against its drawbacks:
Benefits:
Drawbacks:
Most patients find that modest lifestyle adjustments can manage constipation without sacrificing Zepbound's benefits. Open communication with your healthcare provider ensures you stay on the most appropriate regimen for your health goals.
Remember, any serious or life-threatening symptoms should prompt immediate medical consultation. Your healthcare provider can help tailor a plan that balances treatment efficacy with quality of life.
(References)
* Wang Y, Ma X, Ma W, Zhang Z, Tian Y. Gastrointestinal adverse events associated with tirzepatide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Endocrinol Metab. 2022 Jun 15;13:20420188221107576. doi: 10.1177/20420188221107576. PMID: 35711689; PMCID: PMC9201550.
* Li M, Wang Y, Zheng X, Cai H, Liu H, Xu W, Wu J, Wang H, Zhang M, Lin C. Safety and tolerability of tirzepatide in overweight and obese individuals without diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023 Jan 26;14:1120002. doi: 10.3389/fendo.2023.1120002. PMID: 36761002; PMCID: PMC9909249.
* Han H, Li Y, Han T, Li P, Hu W, Li Y, Hu K, Suo M, Zhai Y, Liu H, Shi H, Zhang S, Hu C. Comparison of Adverse Events of Tirzepatide, Semaglutide, and Liraglutide: A Disproportionality Analysis. Front Pharmacol. 2023 Jan 24;14:1107931. doi: 10.3389/fphar.2023.1107931. PMID: 36779379; PMCID: PMC9896755.
* Chen X, Luo Y, Chen C, Guo Z, Li J. Management of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists. Diabetes Metab Syndr Obes. 2024 Jan 5;17:15-28. doi: 10.2147/DMSO.S441434. PMID: 38202450; PMCID: PMC10787343.
* Singh RK, Gill A, Arora T, Grewal P, Naran S, Palabindala V, Akolkar G, Shah A, Palanisamy S, Kumar R. Tirzepatide: Efficacy and Safety in Diabetes and Obesity. Cureus. 2023 Jul;15(7):e41460. doi: 10.7759/cureus.41460. PMID: 37577884; PMCID: PMC10403310.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.